Dharmacon, Inc.

Thermo Fisher Scientific Gmbh

Becton Dickinson and Company Limited

Thermo Fisher Scientific Biosciences Inc.

Miragen Therapeutics, Inc.

Other

Merck + Co., Inc.

Amgen Inc.

Merck Sharp + Dohme Corp.

William Marshall

Devin Leake

Anastasia Khvorova

Angela Reynolds

Stephen Scaringe

Steven Read

Bart David Peterson

Elizabeth Nelson

Barbara Robertson

Kathryn Robinson

Weston F Harding

Christina Marie Dalby

Kurt Vagle

David Feygin

Karthik Ranganathan

Ralph Lee Sonderegger

Peter S Linsley

Bryan Garret Davis

Eva Van Rooij

Rusty L Montgomery

Christina Yamada

Kevin Lee Stark

David Richard Stonehouse

James R Ladine

Richard Byrd

Anastasia Khvorava

Yuriy Fedorov

Kimberly Nichols

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.

Methods and compositions for selecting siRNA of improved functionality

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for LDHA.

siRNA targeting LDHA

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for HAO1.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for COX-2.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for F12.

Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for ZNF205.

RNAi targeting ZNF205

Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for CNTD2.

RNAi targeting CNTD2

Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for SEC61G.

RNAi targeting SEC61G

The present invention relates to oligonucleotides with base modified nucleosides for enhancement of binding affinity.

Base modified oligonucleotides

A system for recording the wasting of fluids includes a waste disposal unit and a sensor system, having a sensor. The sensor can have one or more sensor elements in fluid communication with a fluid as it is wasted from a container into the waste disposal unit. The sensor system is configured to identify one or more drugs within the fluid and record the identity of the one or more drugs in a computer-readable medium electrically coupled to the sensor system.

Smart medication waste disposal

Growing community of inventors

Boulder, CO, United States of America

William Marshall